APA (7th ed.) Citation

Ullmann, M., Seipel, K., Nilius, H., Bertschinger, M., Rentsch, V., Bacher, U., & Pabst, T. (2026). Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab. Cancers, 18(6), 930. https://doi.org/10.3390/cancers18060930

Chicago Style (17th ed.) Citation

Ullmann, Maeva, Katja Seipel, Henning Nilius, Martina Bertschinger, Vera Rentsch, Ulrike Bacher, and Thomas Pabst. "Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab." Cancers 18, no. 6 (2026): 930. https://doi.org/10.3390/cancers18060930.

MLA (9th ed.) Citation

Ullmann, Maeva, et al. "Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab." Cancers, vol. 18, no. 6, 2026, p. 930, https://doi.org/10.3390/cancers18060930.